RSVAlert website is undergoing maintenance. You may experience some temporary delays.

About the RSVAlert® Surveillance Program

What is RSVAlert?

  • RSVAlert is AstraZeneca's RSV Surveillance Program. It is facilitated and managed by IMS, a company with longstanding experience in viral illness tracking and surveillance, to characterize and report RSV activity at the local level.
  • IMS is a leading provider of real-time localized illness tracking and patient-level analyses and data modeling. IMS has operated the RSVAlert program since 2004.
  • Laboratory RSV test results are submitted directly to IMS weekly each year via fax, web reporting (www.reportnowonline.com), or email (rsvalert@us.imshealth.com), and provide up-to-date information.
  • All data is de-identified before receipt. Only total tests and total positives are collected and then aggregated at the local level for reporting.
  • RSVAlert provides local level coverage of the Core Based Statistical Areas (CBSAs) in the United States.

 

What are the goals of the program?

  • The RSVAlert Surveillance Program is funded by AstraZeneca to:
    • Identify RSV activity as it occurs throughout the United States.
    • Provide data that can differentiate RSV activity at the local, state, and national levels.

 

What about the CDC?

 

Why are there differences in the way data are reported between the NREVSS site and RSVAlert.com?

  • RSVAlert includes all test types (antigen, culture, and PCR) and reports all information as provided. Generally, NREVSS only reports RSV antigen detection test results.

 

What's included in RSVAlert?

  • RSVAlert focuses on data from hospital laboratories. Approximately 480 laboratories have agreed to report their RSV data, including antigen detection, virus isolation, and polymerase chain reaction (PCR) results.
  • RSVAlert laboratory coverage is focused on Core Based Statistical Areas (CBSAs).
    • CBSA is the official term for a geographic region based around an urban center of at least 10,000 people, based on standards published by the Office of Management and Budget.
  • Note that hospitals have a variety of protocols regarding which patients get tested for RSV, when testing begins and ends, and what kind of tests are used.

 

What information will I receive?

  • Within each CBSA represented in RSVAlert, IMS will prepare a weekly report each year showing total number of RSV tests, total number of RSV-positive tests, and percentage of RSV-positive tests.  The information will also be charted graphically.
    • A data table below the graph shows data for each week for that area.
    • All participating laboratories in RSVAlert that are located in the selected CBSA or state will display below the data table.
    • A minimum number of laboratories are required in order to display a CBSA report.  If a CBSA does not meet the requirements this message will appear, "Sorry, but data for this area is not currently available." Once the number of recruited laboratories in this area meets that criterion, their data will begin displaying on RSVAlert.
    • Weekly reports each year are provided on RSVAlert.com.

 

 Why does RSVAlert data not match that on a state or public health website?

  • RSVAlert provides weekly reports ending each Saturday and depending on the state or public health website, they may report different timeframes and have different protocols.
  • RSVAlert only includes primary tests in the data results. Some sites include both culture confirmation and primary tests in their results.